Research programme: human papilloma virus vaccines - HERVOLUTION Therapeutics
Latest Information Update: 28 Mar 2024
At a glance
- Originator InProTher
- Developer HERVOLUTION Therapeutics
- Class Papillomavirus vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Human papillomavirus infections
Most Recent Events
- 28 Mar 2024 No recent reports of development identified for preclinical development in Human-papillomavirus-infections in Denmark
- 13 Feb 2020 Human papilloma virus vaccines are available for licensing as of 13 Feb 2020. https://www.inprother.com/contact/
- 07 Feb 2020 Preclinical development in Human papillomavirus infections is still ongoing in Denmark